Difference between revisions of "Uy GL, et al. Blood (2012) cited as Ref 630 in DOI: 10.1038/s41392-020-0110-5 (Q9893)"
Jump to navigation
Jump to search
(Created claim: DOI Identifier (P138): 10.1182/blood-2011-10-383406, #quickstatements; #temporary_batch_1590000649558) |
(Created claim: Page(s) (P105): 3917-3924, #quickstatements; #temporary_batch_1590074839150) |
||||||||||||||
| (5 intermediate revisions by the same user not shown) | |||||||||||||||
| Property / PubMed ID | |||||||||||||||
| + | |||||||||||||||
| Property / PubMed ID: 22308295 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Publication Date | |||||||||||||||
| + | 2012
| ||||||||||||||
| Property / Publication Date: 2012 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Published In Name String | |||||||||||||||
| + | Blood | ||||||||||||||
| Property / Published In Name String: Blood / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Volume | |||||||||||||||
| + | 119 | ||||||||||||||
| Property / Volume: 119 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / title | |||||||||||||||
| + | A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia (English) | ||||||||||||||
| Property / title: A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia (English) / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Page(s) | |||||||||||||||
| + | 3917-3924 | ||||||||||||||
| Property / Page(s): 3917-3924 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
Latest revision as of 15:47, 21 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Uy GL, et al. Blood (2012) cited as Ref 630 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Uy GL
0 references
2012
0 references
Blood
0 references
119
0 references
A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia (English)
0 references
3917-3924
0 references
